The company has appointed Dr Lars Nieba as Chief Technology Officer and a member of the executive management team.
Dr Nieba brings 20 years of leadership experience in the development of multiple pharmaceutical product candidates and innovative technologies. His role at Nordic Nanovector will be to oversee all Chemistry, Manufacturing and Controls (CMC) strategic and operational aspects of Betalutin and all other pharmaceutical products developed by the company.
“Lars is an important hire for Nordic Nanovector, bringing valuable complementary expertise to the executive team. He will play a crucial role in refining and executing our CMC strategy for Betalutin® in non-Hodgkin’s lymphoma as well as for the other assets in our emerging pipeline of targeted radioimmunotherapies. We are pleased to welcome Lars to the team,” says Eduardo Bravo, Nordic Nanovector’s Chief Executive Officer.
“Betalutin is a very exciting new treatment”
Dr Nieba will join Nordic Nanovector on 1 December 2019 from Bayer AG, where he served as VP and Strategic Product Lead, responsible for driving Bayer’s CMC strategy related to CMC product development, product supply and life cycle management of certain of its products (e.g. EYLEA). He joined Bayer in 2016 following 13 years at F. Hoffmann-La Roche Ltd., at which he held leadership roles in clinical supply planning, biologics technology and technical business development biologics.
Dr Nieba gained a PhD from the Max-Planck-Institute for Biochemistry, München and Institute for Biochemistry at the University of Zürich, and an Executive MBA; University of St. Gallen, Switzerland. He holds dual Swiss/German nationality and is a Swiss resident.
“I am delighted to be joining Nordic Nanovector. Betalutin is a very exciting new treatment, since this novel targeted radioimmunotherapy offers a clearly differentiated therapy option for patients with non-Hodgkin’s lymphoma. I look forward to using my knowledge and expertise to make an important contribution to Nordic Nanovector’s future success and to ensure that we are well prepared for regulatory filings for Betalutin, both in the USA and Europe,” says Lars Nieba.
